Shots:
- Akeso has reported P-Ib/II study data assessing cadonilimab + anlotinib & docetaxel in pts with locally advanced or metastatic NSCLC who progressed after prior PD-(L)1 inhibitor-based therapy
- At mFU of 21.45mos., the trial showed 6mos. PFS rate of 55.7%, with an mPFS of 7mos. in the overall population, while in sq-NSCLC & PD-L1 TPS ≥1% subgroups mPFS was 7.5 & 7.4mos. respectively
- Additionally, the trial showed DCR of 95.2%, ORR of 26.2% & mDoR of 6mos., while pts with ctDNA clearance had mPFS of 9.1mos. After the first treatment cycle, the ctDNA detection rate declined from 1.5% to 0.5%. Data were presented at ELCC’26
Ref: PRnewswire | Image: Akeso | Press Release
Related News: Akeso Presents P-II (COMPASSION-03) Trial Data on Cadonilimab for R/M Cervical Cancer at ESGO 2026
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
